Moderna’s mFlusiva, the first FDA-approved mRNA flu vaccine.

Moderna Wins FDA Approval for the First mRNA Flu Vaccine

mFlusiva expands mRNA technology beyond COVID-19 and into the seasonal influenza market.


Key Takeaways

  • The FDA approved mFlusiva (mRNA-1010) for seasonal influenza prevention in adults aged 50 and older, making it the first mRNA-based flu vaccine approved in the U.S.
  • In adults aged 50 and older, mFlusiva showed 26.6% higher relative vaccine efficacy than a standard-dose flu vaccine.
  • The approval gives Moderna an important opportunity to extend its mRNA platform into a large, recurring seasonal vaccine market.

Data Snapshot

ItemDetails
ProductmFlusiva
Development codemRNA-1010
DeveloperModerna
IndicationSeasonal influenza prevention
Approved populationAdults aged 50+
TechnologymRNA vaccine
50–64 yearsTraditional approval
65+ yearsAccelerated approval
U.S. launchExpected for the 2026–2027 flu season

The approval is split by age group: adults aged 50–64 received traditional approval, while approval in those aged 65 and older is contingent on a postmarketing confirmatory study.


What Happened

The FDA approved Moderna’s mFlusiva on August 5, 2026, for prevention of seasonal influenza in adults aged 50 years and older. (Link) The decision makes mFlusiva the first U.S.-approved influenza vaccine based on messenger RNA technology and Moderna’s fourth approved product in the country. Moderna expects to make the vaccine available for the 2026–2027 influenza season.

The approval followed an unusual regulatory path. Earlier in 2026, the FDA initially declined to review Moderna’s application over concerns about the Phase 3 comparator, before reversing that decision. An FDA advisory committee later voted unanimously that the vaccine’s benefits outweighed its risks. (Link)


Why It Matters

mFlusiva uses mRNA instructions to direct cells to produce influenza antigens, allowing the immune system to recognize those viral targets and generate protective immunity. The basic principle is similar to Moderna’s COVID-19 vaccines, but the platform is now being applied to seasonal influenza. (Link)

In a Phase 3 efficacy trial, mFlusiva demonstrated 26.6% relative vaccine efficacy versus a standard-dose influenza vaccine in adults aged 50 years and older. In adults 65 and older, Moderna compared the vaccine with a high-dose inactivated flu vaccine, with immune response serving as the primary objective. (Link)

The broader significance extends beyond efficacy. Traditional influenza vaccines depend on manufacturing processes that require strain selection well before each flu season. An mRNA platform could potentially allow faster redesign and manufacturing when circulating strains change, although real-world manufacturing and distribution will determine how much of that theoretical advantage is realized.


BP View

The approval of mFlusiva is important because it shows that mRNA technology can expand beyond COVID-19 and into a recurring seasonal vaccine market.

For patients, another influenza vaccine option is welcome, particularly if the platform can eventually enable faster adaptation to circulating strains. However, pricing, tolerability, manufacturing efficiency and real-world effectiveness will ultimately determine how widely mFlusiva is adopted.

Moderna’s initial focus on adults aged 50 to 64 may also reflect a strategic clinical-development choice, as immune responses are generally more robust than in older adults. The next question is how successfully Moderna can expand its evidence and indications across broader age groups, particularly the elderly.

For Moderna, mFlusiva is another opportunity to prove that mRNA is not a single-product technology, but a reusable platform capable of supporting multiple infectious-disease franchises.


Related Post

For another example of how a differentiated therapeutic approach could create a new treatment option in an underserved disease, read our previous analysis of Tarsus’ acquisition of Alkeus and gildeuretinol for Stargardt disease.


About BP

Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.


Comments

Leave a Reply